This morning Kamada released a note at TASE that they received a positive review regarding its program to test its inhaled AAT in phase II clinical trials for the treatment of Cystic Fibrosis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.